Page 1

Due to rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical practice, humanized mAbs have turnout to be fastest growing group of biotechnologyderived molecules in clinical trials. Driven by the growing application area pertaining to target disease viz. cancers, autoimmune disorders, infectious diseases, the monoclonal antibody market was valued over US$ 100 billion in 2017 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of XX% to reach US$ XXX by year 2023. Although various small molecule kinase inhibitors have been approved for targeting VEGF induced signaling, but the use of mAbs against VEGF have been established since FDA approval of Bevacizumab (Avastin, Genentech/Roche) in year 2004. Since, Avastin, FDA has approved ranibizumab (Lucentis, Genentech/Roche) and aflibercept (Eylea, Regeneron Pharma) both for cancer treatment and age related macular degradation (AMD). Therefore, use of mAbs in targeting VEGF induced angiogenesis in cancer, inflammation, arthritis and AMDs have tremendous potential in near future. Company profile mentioned: Roche, Novartis, Sanofi, Regeneron, Bayer, AstraZeneca Market segmentation: By Geography - North America, South America, Europe, Asia-Pacific Download Free Sample at: http://www.ingeniousreports.com/industry/healthcare-market-reports/antivegf-antibodies-global-technology-assessment-market-analysis-and-future-growth-trends The report includes following key insights:

      

In this report we discuss the novel technologies/methodologies used for production, purification, structural modifications and formulation of mAbs against VEGF ligands in various human pathologies using technology distribution based on IP analysis The report highlights the significant trends in efficacy, limitations and patient survival rate anti-VEGF antibodies therapy based on data available for Avastin, Lucentis, Eylea, Vanucizumab, Brolucizumab and hPV19 This report showcases the competitive benchmarking of key industrial players like Roche, Sanofi, Novartis, Regeneron Pharma, AbbVie etc. in development of anti-VEGF antibodies from laboratory to clinical trials Product search and market forecast for trends in anti-VEGF mAbs will be extensively described The report will further include detailed description of anti-VEGF antibodies in clinical trials and their beneficial effects on targeted patients especially cancer and age related macular degradation, autoimmune diseases Report includes driving factors influencing global anti-VEGF mAbs market for year 2017-2022 Detailed description of SWOT and PEST analysis in development of anti-VEGF antibody therapy

Table of Contents: 1. Technology Overview 1.1. List of Tables sales@ingeniousreports.com www.ingeniousreports.com


1.2. List of Figures 1.3. Introduction 1.4. Objective & Scope 1.5. Research Methodology 2. Anti-VEGF antibodies: Technology Segmentation 2.1. Technology distributions 2.1.1. Anti-VEGF antibody sequences 2.1.1.1. Nucleotide sequences 2.1.1.2. Amino acid sequences 2.1.2. Anti-VEGF antibody expression systems 2.1.2.1. Prokaryotic expression vectors systems 2.2.2.2. Eukaryotic expression vectors systems 2.1.3. Anti-VEGF antibody production host cells/organisms 2.1.3.1. E. coli as host for antibody production 2.1.3.2. Yeast as host for antibody production 2.1.3.3. CHO cells as host for antibody production 2.1.3.4. Any other host system for antibody production 2.1.4. Anti-VEGF antibody host culture medium 2.1.4.1. Prokaryotic culture medium specific composition 2.1.4.2. Eukaryotic Culture medium specific composition 2.1.5. Anti-VEGF antibody purification methods 2.1.5.1. Affinity chromatography 2.1.5.2. Hydrophobic interaction chromatography 2.1.5.3. Ion exchange column chromatography 2.1.5.3.1. Anion exchange chromatography 2.1.5.3.2. Cation exchange chromatography 2.1.5.4. High performance-size exclusion chromatography 2.1.5.5. Any other methods for purification 2.1.6. Anti-VEGF nucleotides delivery to target site 2.1.6.1. Viral vectors for targeted delivery 2.1.6.1.1. Adenovirus 2.1.6.1.2. Adeno-associated virus (AAV) 2.1.6.1.3. Lentivirus 2.1.6.1.2. Virus-like particles (VLPs) 2.1.6.2. Any other vector system used 2.2. Anti-VEGF antibodies in clinical trials/approved by FDA/EMA 2.2.1. Bevacizumab/Avastin 2.2.2. Ranibizumab/Lucentis 2.2.3. Aflibercept/Eylea 2.2.4. Vanucizumab 2.2.5. Brolucizumab 2.2.6. hPV19 2.2.7. VGX-100 2.2.8. Sevacizumab sales@ingeniousreports.com www.ingeniousreports.com


2.2.9. HuMV833 3. Anti-VEGF antibodies: Global IP Trends 3.1. Geographic Activity 3.1.1. United States 3.1.1.1 Top players in United States 3.1.1.2 Important IPs in United States 3.1.2. Europe 3.1.2.1 Top players in Europe 3.1.2.2 Important IPs in Europe 3.1.3. Asia 3.1.3.1 Top players in Asia 3.1.3.2 Important IPs in Asia 3.2. Technology Breakdown- Distribution of Anti-VEGF antibodies 3.2.1. IP claiming Sequences for anti-VEGF antibodies 3.2.2. IP claiming expression systems for anti-VEGF antibodies 3.2.3. IP claiming host cells/organisms for production of anti-VEGF antibodies 3.2.4 IP claiming methods for production and purifications 3.2.5. IP claiming delivery vectors for anti-VEGF antibodies 3.3. Competitive Intelligence: Anti-VEGF antibodies 3.3.1. Technology distribution and comparison between key players including institutes/universities/industry 3.3.1. Sequence-based comparison of key players 3.3.2. Expression vector-based comparison of key players 3.3.3. Host cells/organisms-based comparison of key players 3.3.4. Culture medium composition-based comparison of key players 3.3.5. Targeted delivery system-based comparison of key players 3.3.6. Purification methodology-based comparison of key players 3.4. Collaborations / Acquisitions / Licensing Activity of key players in Anti-VEGF antibodies: 3.4.1. Collaboration between companies 3.4.2. Collaboration between company and universities 3.4.3. Licensing activity among universities, companies and individuals 3.4.4. Acquisition in the Anti-VEGF antibodies technology domain 4. Anti-VEGF antibodies: Different diseases targeted 4.1. Anti-VEGF antibody therapy for cancer 4.1.1. Anti-VEGF antibody therapy for colorectal cancer 4.1.2. Anti-VEGF antibody therapy for glioblastoma 4.1.3. Anti-VEGF antibody therapy for breast cancer 4.1.4. Anti-VEGF antibody therapy for renal carcinoma 4.1.5. Anti-VEGF antibody therapy for metastatic lung tumors 4.1.6. Anti-VEGF antibody therapy for any other cancer 4.2. Anti-VEGF antibody therapy for retinopathy 4.2.1. Anti-VEGF antibody therapy for age-related macular degeneration 4.2.2. Anti-VEGF antibody therapy for macular edema 4.2.3. Anti-VEGF antibody therapy for diabetic macular edema (DME)

research

sales@ingeniousreports.com www.ingeniousreports.com


4.2.4. Anti-VEGF antibody therapy for diabetic retinopathy (DR) 4.2.5. Anti-VEGF antibody therapy for myopic choroidal neovascularization 4.3. Anti-VEGF antibody therapy for any other disease related to VEGF overexpression/reduced expression 5. Anti-VEGF antibody: White Space Analysis 6. Recent activities in development of anti-VEGF antibody 6.1 Contract / funding information 6.1.1. Contract / funding objective 6.1.2. Contract / funding receiving company information 6.2. Partnership / Collaboration / Licensing 6.2.1. Partnership / Collaboration / Licensing objective 6.2.2. Information of associated companies 6.3. New emerging technologies 6.3.1. Information of associated company 6.3.2. Information of associated inventors 6.4. Undergoing research activities 6.4.1. Information of associated company 6.4.2. Information of associated inventors 7. Anti-VEGF Antibody Technology Opinions from Experts 8. Anti-VEGF Antibody Technology Collaboration Insights 9. Strategies of Companies involved in development of Anti-VEGF antibody 10. Recent Anti-VEGF Antibody Product Developments 10.1. Product overview 10.2. Company information 11. Global Trends Anti-VEGF Antibody Market 12.1. North America 12.2. South America 12.3. Europe 12.4. Asia-Pacific 12. Global Anti-VEGF antibody development: Top Industrial Players 12.1. Roche 12.2. Novartis 12.3. Sanofi 12.4. Regeneron 12.5. Bayer 12.6. AbbVie 12.7. Zymeworks 12.8. Elan Pharma 19.9. Five Prime Therapeutics 12.10. Kymab Ltd 12.11. Pfizer 12.12. AstraZeneca 12.13. Boehringer Ingelheim 13. Anti-VEGF Antibody - Market Determinants sales@ingeniousreports.com www.ingeniousreports.com


14. Anti-VEGF Antibody -Opportunity Vs. Restraints 15. Anti-VEGF Antibody: Strategic Analysis SWOT & PEST 16. Anti-VEGF Antibody Market Development (2017-2022) 17. Conclusion About us: IngeniousReports.com provides you the one-stop solution platform for all your market research pain areas. We partner with leading publishers of Market Intelligence and Technology Intelligence reports worldwide. We provide market research reports to all the industries, individuals and organizations with an objective of assisting them in taking the strategic business decision and grow their revenues. Connect with us at: +1 347 480 2054 sales@ingeniousreports.com

sales@ingeniousreports.com www.ingeniousreports.com

Anti-VEGF Antibodies : Technology Innovations and Technology opportutinies by 2023  

Due to rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical practice, humanized mAb...

Anti-VEGF Antibodies : Technology Innovations and Technology opportutinies by 2023  

Due to rapid advancements in genetic sequencing and the translation of basic medical sciences research into clinical practice, humanized mAb...

Advertisement